Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biodistribution and Pathophysiology Study of 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

NCT07077213 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT07077213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07077213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biodistribution and Pathophysiology Study of 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Observational
Overall status
Recruiting
Start date
March 12, 2026
Completion date
December 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis, pulmonary